Bridge Biotherapeutics has launched a Phase 2a clinical trial to assess the safety, tolerability, and effectiveness of BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05483907) is expected to enroll around 120 IPF patients, ages 40 and older, in 50 clinical sites in North America,…
News
The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing research to improve the outcomes of people with pulmonary fibrosis (PF). Each investigator will receive a two-year research grant totaling $100,000, which is an increase of $25,000 a scholar…
Following the successful completion of preclinical studies, Saniona is now ready to initiate the regulatory process needed to start testing SAN903 — its therapy candidate for idiopathic pulmonary fibrosis (IPF) and other disorders — in Phase 1 human trials. “Preclinical data for SAN903 are very compelling,” Thomas Feldthus,…
Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with idiopathic pulmonary fibrosis (IPF), according to a new study. More than half of patients experienced treatment-related adverse events, the majority being non-severe gastrointestinal symptoms. Rare cases of serious heart-related…
Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also includes FIBRONEER-ILD, a similar Phase…
AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…
A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are more likely to experience progressive decline in their lung function, according to new data. Called the Envisia Genomic Classifier, the test works by identifying the genomic…
The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability, and play a key role in lung repair after injury — may be responsible for driving pulmonary fibrosis (PF). That’s according to new findings from a team led by…
The first patient has been enrolled in a Phase 3 clinical trial of Tyvaso (treprostinil) inhalation solution for patients with idiopathic pulmonary fibrosis (IPF), according to the therapy’s developer, United Therapeutics. Called TETON 2 (NCT05255991), the trial will evaluate the treatment’s efficacy against a placebo in about…
BenevolentAI has identified a new treatment target for idiopathic pulmonary fibrosis (IPF) that will be added to AstraZeneca’s therapeutic discovery portfolio. This is the third IPF target identified by the platform for the biopharmaceutical company following previous discoveries. Another AI-generated target for chronic kidney disease (CKD)…
